Previous 10 | Next 10 |
Natera press release (NASDAQ:NTRA): Q4 GAAP EPS of -$1.48 misses by $0.18. Revenue of $173M (+53.9% Y/Y) beats by $4.19M. Outlook: Natera anticipates 2022 total revenue of $770 million to $790 million. Q1 Consensus Revenue Estimate $172.85M; 2022 Consensus Revenue Estimate $761.54M. 2022...
Natera Reports Fourth Quarter and Full Year 2021 Financial Results PR Newswire AUSTIN, Texas , Feb. 24, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today reported financial results for the fourth quarter and ye...
Natera Announces Fourth Quarter and Fiscal 2021 Earnings Conference Call PR Newswire AUSTIN, Texas , Feb. 17, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will release results for ...
Natera Announces Results of Large, Multi-Center Clinical Experience Study Showing Excellent Positive Predictive Value of the Prospera™ Kidney Test PR Newswire AUSTIN, Texas , Feb. 17, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in...
Landmark CIRCULATE-Japan Study Shows Natera's Signatera™ MRD Test is Predictive of Chemotherapy Benefit in Colorectal Cancer Analysis of 1,000+ patients, with 12 months mean follow up, demonstrates clinical utility of Signatera for informing post-surgical treatment decisi...
Blinded, prospective, multi-site trial shows the most common microdeletion can be detected non-invasively with a low false positive rate Natera, Inc. (NASDAQ: NTRA), a leader in personalized genetic testing and diagnostics, today announced the publication of the landmark...
Natera to Present Latest Signatera™ MRD Data in Colorectal and Pancreatic Cancers at the ASCO GI Symposium 2022, and Host Special Investor Call Oral presentations to include largest analysis to date from the prospective CIRCULATE-Japan study and results from first study s...
Dr. Alexey Aleshin to take on new role as GM of early cancer detection at Natera Natera, Inc. (NASDAQ: NTRA), a leader in personalized genetic testing and diagnostics, today announced its expansion into the early cancer detection (ECD) market to advance the companyȁ...
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Natera, Inc. (“Natera” or the “Company”) (NASDAQ: NTRA) on behalf of Natera stockholders. Our investigation concerns whether Natera...
Natera to Webcast Live Presentation at the 40th Annual J.P. Morgan Healthcare Conference PR Newswire AUSTIN, Texas , Jan. 4, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in personalized genetic testing and diagnostics, today announced that ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-23 12:58:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-13 10:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...